TG103 22.5 mg

DRUG3 trials

Sponsors

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Conditions

ObesityOverweightOverweight or Obesity

Phase 2

A Study of TG103 Injection in Overweight or Obesity

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Overweight or Obesity

Start: 2022-05-20End: 2023-09-30Target: 195Updated: 2022-05-23

A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

CompletedNCT06226090

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Obesity, Overweight

Start: 2024-02-21End: 2024-10-24Updated: 2025-05-14

Phase 3

A Study of TG103 Injection in Non-diabetic Overweight or Obesity

CompletedNCT05997576

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Overweight or Obesity

Start: 2023-11-22End: 2025-03-03Updated: 2025-08-11

Related Papers

Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.

2024-05-293 citations